European rights to non-opioid severe chronic pain treatment Prialt transferred to Riemser

Berlin, April 23, 2018 – Riemser Pharma GmbH (Riemser), a specialty pharmaceuticals company operating throughout Europe, announced today that it has entered into an agreement with Japanese Eisai Co., Ltd. (Eisai) to obtain the exclusive development and marketing rights for the non-opioid pain therapy product Prialt® (ziconotide acetate) in Europe. Eisai receives a one-time contractual payment from Riemser in return. Prialt® is currently marketed in twelve European countries and is used to treat patients with severe chronic pain. The parties have agreed confidentiality on economic details of the agreement.

Prialt® is a non-opioid intrathecal infusion for the treatment of severe chronic pain. The drug is injected directly into the spinal canal via an implanted ‘pain pump’. Unlike opioids, ziconotide acetate – the active substance used in Prialt® – does not lead to the development of tolerance or addiction and thus is better suited for prolonged administration.

With five locations in Germany, France and England as well as a global distribution network, Riemser is a pan-European specialty pharmaceutical company that has particular strengths in the marketing and distribution of pharmaceuticals in niche areas of oncology, neurology, infectious diseases and other fields. Transferring the rights to Prialt® to Riemser with its strong distribution network will enable a greater contribution to patients with severe chronic pain in Europe.

Konstantin von Alvensleben, CEO of Riemser, said: “The acquisition of Prialt is strengthening one of our core indication areas Neurology. As the drug’s scope of application is highly specialized and, similarly to our supportive oncology pharmaceuticals, aims at improving patients’ quality of life, Prialt is perfect match with Riemser’s profile.”


About Riemser Pharma GmbH

Riemser Pharma GmbH was established in 1992 and emerged from the Friedrich Löffler Institute on Riems Island (Greifswald). Riemser has been in business for more than 25 years, during which it has evolved from a manufacturer of veterinary medicines to a successful provider of specialty pharmaceuticals for therapeutic niches in the field of human medicine.

Riemser sells, licenses, markets and distributes pharmaceutical products. Over 400 approvals worldwide, of which 28 took place in the last three years, are a testament to the special expertise of Riemser for the approval and opening of new markets for pharmaceutical products.

The product range especially covers prescription drugs to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, in the cardiovascular field, in dermatology, rheumatology, tuberculosis treatment, for the treatment of obesity and primary axillary hyperhidrosis. Medicinal products and food supplements complement the portfolio.

Besides its international group headquarters in Berlin, the company has three locations in Germany. In 2014 and 2015 Riemser acquired the subsidiaries Keocyt based in France and Intrapharm based in England. In addition, it has established an international distribution network. Riemser is a portfolio company of Ardian, one of the world’s leading private investment companies.

For more information, please visit


About Eisai Co., Ltd.

Eisai Co., Ltd. defines its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Oncology and Neurology.

Furthermore we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit


Press Contact

Charles Barker Corporate Communications GmbH
Jan P. Sefrin
Tel: +49 69 79409026

Tobias Eberle
Tel: +49 69 79409024